SCHEMBL3015983

SCHEMBL3015983

Cc1ccc(C)c(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4Cl)CC3)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 1/20 0.42
LPAR2 Q9HBW0 1/20 0.42
TRPV4 Q9HBA0 1/20 0.41
ALDH1A1 P00352 3/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
EPHX2 P34913 1/20 0.41
HSD11B1 P28845 1/20 0.40
MAPT P10636 3/20 0.39
LMNA P02545 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
THRB P10828 1/20 0.39
KDM2B Q8NHM5 1/20 0.39
POLB P06746 1/20 0.39
TP53 P04637 1/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014116 0.93 MAPT (0.44) ALDH1A1RAB9ASMN1; SMN2L3MBTL1MAPT
SCHEMBL3007657 0.92 SMN1; SMN2 (0.41) ALDH1A1RAB9ASMN1; SMN2L3MBTL1MAPT
SCHEMBL3022709 0.92 ALDH1A1 (0.39) LPAR1LPAR2ALDH1A1RAB9ASMN1; SMN2
SCHEMBL3002483 0.91 ALDH1A1 (0.41) ALDH1A1RAB9ASMN1; SMN2L3MBTL1MAPT
SCHEMBL3007799 0.91 ALDH1A1 (0.43) ALDH1A1RAB9ASMN1; SMN2L3MBTL1EPHX2
SCHEMBL3009039 0.90 TRPV4 (0.47) LPAR1LPAR2TRPV4ALDH1A1SMN1; SMN2
SCHEMBL3013342 0.89 TRPV4 (0.45) LPAR1LPAR2TRPV4ALDH1A1RAB9A
SCHEMBL3010663 0.89 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2L3MBTL1HSD11B1MAPT
SCHEMBL3012559 0.88 MAPT (0.49) ALDH1A1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL3009591 0.88 LPAR1 (0.42) LPAR1LPAR2TRPV4RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LPAR1 2066/4885LPAR2 1732/4885TRPV4 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.